Exploring the impact of mifepristone’s risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics()

OBJECTIVES: In 2000, the United States’ Food and Drug Administration (FDA) approved mifepristone for medication abortion. In this article, we explore how the Risk Evaluation and Mitigation Strategy (REMS) criteria for mifepristone specifically impede family physicians’ ability to provide medication...

Descripción completa

Detalles Bibliográficos
Autores principales: Razon, Na’amah, Wulf, Sarah, Perez, Citlali, McNeil, Sarah, Maldonado, Lisa, Byrne Fields, Alison, Carvajal, Diana, Logan, Rachel, Dehlendorf, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018589/
https://www.ncbi.nlm.nih.gov/pubmed/35131289
http://dx.doi.org/10.1016/j.contraception.2022.01.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018589/
https://www.ncbi.nlm.nih.gov/pubmed/35131289
http://dx.doi.org/10.1016/j.contraception.2022.01.017

Ejemplares similares